01
Jun
2022
12:30
BST
19:30
SGT
Webinar
Inclisiran: A Jab Goes a Long Way
-
Views:
4453
-
Likes:
17
Overview
High levels of low-density lipoprotein (LDL) cholesterol can increase the risk of atherosclerosis and cardiovascular events such as a heart attack or stroke. Inclisiran, now approved by NICE (2021) can be used to reduce LDL cholesterol.
Do you know when, how and on which patients to use the novel anti-cholesterol drug inclisiran to treat elevated LDL in patients with hypercholesterolaemia, mixed dyslipidaemia or patients that have had a previous cardiovascular event?
Join our webinar and learn more during an interactive panel discussion, showcasing real-world case applications of this new agent, produced as part of the ISCP series on the A to Z of CV Pharmacotherapy.
Led by moderators Dr Krittin Bunditakanul (Bangkok, Thailand) and Dr Doreen Tan (Singapore), it includes a speaker presentation from Prof Kyzysztof Filipiak (Warsaw, Poland), two case presentations from Dr Bundaitakanul and discussions from panellists Prof Bernard Cheung (Hong Kong) and Dr Alberto Lorenzatti (Argentina) that will examine the considerations for use of this new agent, through interesting real-world examples, live discussions and audience Q&A.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
Reserve your seat for the next webinar in the series and view on-demand today!
Faculty:
Krzysztof Filipiak
Bernard Man Yung Cheung
Alberto Lorenzatti
Krittin Banditanukul
Doreen Su-Yin Tan
This webinar is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP). The ISCP has been provided support to develop this webinar by Novartis Singapore. The supporter has had no influence on the content of the programme or provided any funding to Radcliffe Cardiology
Key Learning Objectives
- To evaluate and understand which patients should and should not receive inclisiran and which patients groups might benefit most
- To determine how inclisiran should be administered and what dosage adjustments, drug interactions or pharmacogenetic issues need to be noted
- To analyse special and regional issues that impact the use of this agent and evaluate which groups will benefit most
- To apply evidence-based recommendations to two real world cases
Target Audience
- Cardiovascular team members - doctors, nurses and pharmacists
- Family physicians
- Internists
- Cardiovascular pharmacotherapy researchers
Faculty Biographies
Krzysztof Filipiak
Specialist in: cardiology, internal medicine, arterial hypertension, clinical pharmacology (4 certified specializations).
Bernard Man Yung Cheung
Bernard Man Yung Cheung is a Professor in Cardiovascular Therapeutics and heads the Division of Clinical Pharmacology and Therapeutics in the Department of Medicine at the University of Hong Kong's School of Clinical Medicine.
Alberto Lorenzatti
Dr Alberto J. Lorenzatti heads the Lipid Clinic & Cardiovascular Prevention – Cardiology Department – Hospital Córdoba (Cordoba-Argentina).
Krittin Banditanukul
Dr. Krittin has 15 years’ experience in pharmacy practice, with special interest in cardiovascular, diabetes, emergency, critical care and community pharmacy.
Doreen Su-Yin Tan
Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore.